NX Development Corp | Finanzwire

Basculer en Français

9982	Companies
202335	Keywords
132958	Articles
107443	Press releases

Home
Companies
NX Development Corp

BRIEF

published on 06/21/2024 at 15:05, 1 year 8 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)

Gleolan NX Development Corp. OVA-302 Study FDA Orphan Designation
PRESS RELEASE

published on 06/21/2024 at 15:00, 1 year 8 months ago

NX Development Corp. Enrolls First Patient in OVA-302 Study After FDA Orphan Designation for Gleolan(R)
NX Development Corp. enrolls first patient in OVA-302 study for cancer management using Gleolan following FDA's Orphan Designation. CEO DeSena and Chairman Kosciessa express excitement for future programs

Gleolan NX Development Corp. OVA-302 Study Cancer Management Flourescence-guided Surgery
BRIEF

published on 03/05/2024 at 23:05, 1 year 11 months ago

NX Development Corp. Awarded Orphan-Drug Designation for Gleolan in Ovarian Cancer Treatment

FDA NX Development Corp Orphan-Drug Designation Gleolan Ovarian Cancer
PRESS RELEASE

published on 03/05/2024 at 23:00, 1 year 11 months ago

NX Development Corp. is Granted Orphan-Drug Designation Status by US FDA for Gleolan(R) in Ovarian and Related Cancers
NX Development Corp. has achieved orphan-drug status from the FDA for Gleolan, aiding in the visualization of ovarian tumors during surgery. The milestone highlights innovation in cancer care and surgery

FDA Cancer Care Gleolan NX Development Corp. Orphan-drug Status

Accesswire

Published on 03/05/2026 at 14:00, 1 hour 45 minutes ago

EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 1 hour 45 minutes ago

GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 1 hour 45 minutes ago

Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 13:40, 2 hours 5 minutes ago

Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 13:30, 2 hours 15 minutes ago

Vox Royalty Provides 2026 Guidance and Increases Quarterly Dividend

View all ACCESSWIRE

EQS Group

Published on 03/05/2026 at 15:32, 13 minutes ago

Correction of a release from 31.12.2025 07:30 GMT/BST - Restoration- daVictus Plc
Published on 03/05/2026 at 15:07, 37 minutes ago

Form 8.3 - The Vanguard Group, Inc.: NCC Group plc
Published on 03/05/2026 at 15:07, 38 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 03/05/2026 at 15:06, 39 minutes ago

Form 8.3 - The Vanguard Group, Inc.: British Land Company plc, The
Published on 03/05/2026 at 15:05, 39 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc

Les Echos

Published on 03/05/2026 at 13:20, 2 hours 24 minutes ago

Voting rights
Published on 03/05/2026 at 07:30, 8 hours 15 minutes ago

Share buyback finalized
Published on 03/04/2026 at 23:50, 15 hours 55 minutes ago

Total number of voting rights and shares making up the share capital at February 28, 2026
Published on 03/04/2026 at 18:00, 21 hours 44 minutes ago

Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 22 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE